Continuing the public benefit of CPDB

Dr Nicholas Marchetti Product Manager nik.marchetti@lhasalimited.org



Leaders in the development of expert chemoinformatic systems and trusted curators of proprietary data.

Who are Lhasa Limited?

- Established in 1983
- Not-for-profit organisation
- Educational Charity
- Controlled by our members
- Knowledge base, Statistical and Database systems



What is CPDB

The Carcinogenic Potency Project

- Carcinogenic Potency DataBase
- Database for carcinogenic effect and calculated TD₅₀ (tumour dosage) values of over 1500 compounds



Carcinogenic Compound Dosage (ug/g)

Carcinogenic Compound Dosage (ug/g)	Tumoured Animals (N)	Total Animals (N)	Tumoured Animals/Total Animals
0.0	1	13	0.08
2.6	1	13	0.08
5.9	2	12	0.16
11.2	4	13	0.30
23.7	8	12	0.66
51.2	10	12	0.83
112.4	12	12	1.00

What is CPDB

The Carcinogenic Potency Project

- Carcinogenic Potency DataBase
- Database for carcinogenic effect and calculated TD₅₀ (tumour dosage) values of over 1500 compounds
 - Created to aggregate the results of different publications and groups under the same umbrella
 - Provides a direct comparison between the studies and a subjective quality score
 - Calculated individual studies TD_{50} , as well as general compound one
- Manually curated for over 30 years by Lois Gold (UC Berkeley)
- Seen as a great resource by the community
- No longer supported last update in 2007

Where CPDB excels

- CPDB offered an easy, comparable and unbiased way to compare different studies on the same compound
 - Easy: searching for the CAS number or the compound name showed all carcinogenicity studies linked to it
 - **Comparable:** the database contained an array of information that made it easy to compare the different studies, such as animal model, lineage, mode of injection, injection area, type of tumour and more
 - Unbiased: because they were not content-producers, the commitment was to provide as much information as possible and not value one study over the other without evidence that supported that
- Development of a good method that allows TD₅₀ calculation (with some caveats), accounts for spontaneous tumour generation and takes into consideration the length of the study

Where CPDB falls short



Introducing: Lhasa CarcDB

- We want to expand upon CPDB
 - By maintaining CPDB great features
 - Public database
 - Up-to-date
 - Individual study annotation (animal model, lineage, tumour type...)
 - Calculated TD₅₀
 - By improving on what is available
 - New transparent TD₅₀ calculation method, heavily based on Gold's one, but objective and data-driven (paper coming out soon!)
 - By adding new features
 - Structure-based search, on the top of the standard search by CAS number or common name

Why use Lhasa CarcDB?

- Lhasa is a non-profit organization acting as an unbiased curator
- CarcDB is open and free for all
- We are committing to keep CarcDB updated and supported
 - Imported CPDB and expanding with new studies
 - Currently over 1500 compounds and 6000 studies
- No subjective data analysis
- Reproducible TD₅₀ values
- Structure searchable
- Transparent and accessible TD₅₀ methodology
 - Gold's TD₅₀ are shown next to Lhasa's one so the user has as much information as possible

How is Lhasa CarcDB TD₅₀ calculated?

- Based on Gold's method¹
- Controls for natural tumour occurrence and study length
- Use L-BFGS-B optimization algorithm to identify global *minima* parameters, on 3 or more datapoints
- Subjective data analysis no longer necessary
- Compound TD_{50} is calculated by using a harmonic average on individual studies' TD_{50}
 - Harmonic average: ideal in samples with large diversity, while being a conservative average

CARCINOGENICITY DATABASE



The Lhasa Carcinogenicity Database is a searchable repository of 6529 long-term carcinogenicity studies covering a total of 1529 chemicals. The database builds upon the work done between 1980 and 2005 by Lois Swirsky Gold and her team. For further details, please see https://toxnet.nlm.nih.gov/cpdb.

Some compounds from Gold *et al.* dataset have been combined for the Lhasa Carcinogenicity Database as they represent the same chemical entity (for example at technical grade and commercial grade).

More about...

I want to search by:



© 2016 Lhasa Limited | Registered office: Granary Whan House, 2 Canal Whan, Leeds, LS11 5PS, UK 1et +44 (0)113 394 6020 VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wak

CARCINOGENICITY DATABASE



The Lhasa Carcinogenicity Database is a searchable repository of 6529 long-term carcinogenicity studies covering a total of 1529 chemicals. The database builds upon the work done between 1980 and 2005 by Lois Swirsky Gold and her team. For further details, please see https://toxnet.nlm.nih.gov/cpdb.

Some compounds from Gold *et al.* dataset have been combined for the Lhasa Carcinogenicity Database as they represent the same chemical entity (for example at technical grade and commercial grade).

More about...

I want to search by:





© 2016 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020 VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wale

Accessible site

CARCINOGENICITY DATABASE ABOUT | FIELD DESCRIPTIONS Search by STRUCTURE OTHER PARAMETERS

< Back to results</p>

Captan

Summary

Species	<u>Lhasa TD₅₀ (mg/kg/day)</u>	<u>Gold TD₅₀</u> (mg/kg/day)	Result	Sex	Tumour sites	Notes	
Mouse	1.010	2,110	POSITIVE	♀ Female	Small intestine		
	1,010			O ⁿ Male	Small intestine	9	
<u>Rat</u>	1.110	2.000		Q Female	Uterus		
	1,410	2,080	POSITIVE	O ⁷¹ Male	Kidney	-	

Chemical structure

CAS Number Chemistry unique identifier

133-06-2 133-06-2

Chemistry name

Captan

Synonym(s)

3a,4,7,7a-Tetrahydro-2-[(trichloromethyl)thio]-1H-isoindole-1,3(2H)-dione; N-Trichloromethylthio-4-cyclohexene-1,2-dicarboximide; N-Trichloromethylthiotetrahydrophthalimide; Orthocide; Trichloromethylthio-1,2,5,6-tetrahydrophthalamide

Molecular weight Molecular formula

300.59 C9H8Cl3NO2S

SMILES C1C=CCC2C1C(N(C2=O)SC(Cl)(Cl)Cl)=O



CARCINOGENICITY DATABASE ABOUT | FIELD DESCRIPTIONS

Search by STRUCTURE OTHER PARAMETERS

Lhasa

Study details and citations

expand	all	collapse all

Species Mouse			Sex Male	Strain CD1		Route Diet	Exposure time 113 week(s)	Experiment time 113 week(s)				~
Tumour Sil Small inte	te estine			Tumour Type More than o	e one tumour type			Probability <= 0.0005	POSITIVE	Lhasa TD ₅₀ 956	Gold TD ₅₀ 2690	\sim
Unit	mg/kg/day	mg/kg/day	mg/kg/day	mg/kg/day								
Dose	0	703	1180	1890								
Incidence	3/80	19/80	22/80	39/80								
Tumour Sit Small inte	te estine			Tumour Type Carcinoma	3			Probability <= 0.0005	POSITIVE	Lhasa TD ₅₀ 1450	Gold TD ₅₀ 3500	>
Tumour Sil Small inte	te estine			Tumour Type Adenoma	è			Probability <= 0.002	POSITIVE	Lhasa TD ₅₀ -	Gold TD ₅₀ 8280	>
Literature	reference	(s)										>
Notes (exp	oosure, his	stopatholo	gy, mortali	ity)								>
Species Mouse			Sex Fema	Strain ale CD1		Route Diet	Exposure time 113 week(s)	Experiment time 113 week(s)				\sim
Tumour Sit Small inte	te estine			Tumour Type Adenoma	ð			Probability <= 0.035	POSITIVE	Lhasa TD ₅₀ -	Gold TD ₅₀ 13300	>
Tumour Sit Small inte	te estine			Tumour Type Carcinoma	9			Probability <= 0.0005	POSITIVE	Lhasa TD ₅₀ 1320	Gold TD ₅₀ 2110	>
Tumour Sit	te			Tumour Type	•			Probability	POSITIVE	Lhasa TD ₅₀	Gold TD ₅₀	>



305.41 C18H27NO3

C=1(C(=CC=C(C=1)CNC(=O)CCCCC=CC(C)C)O)OC

SMILES C=1(C(=CC=C(C=

InChl



CARCINOGENICITY DATABASE ABOUT | FIELD DESCRIPTIONS

Search by STRUCTURE

OTHER PARAMETERS

Study details and citations

expand all collapse all

Lhasa

Species Mouse		Sex Fer	k Strain male Swiss	Route Diet	Exposure time 152 week(s)	Experiment time 152 week(s)				~
Tumour Site Caecum			Tumour Type Adenoma- polypoid			Probability <= 0.148	POSITIVE	Lhasa TD ₅₀ -	Gold TD ₅₀ 167	~
Dose (mg/kg/day)	0	40.6								
Incidence	4/50	11/50								
Tumour Site Duodenum			Tumour Type Adenocarcinoma			Probability <= 0.253	NOT SPECIFIED	Lhasa TD ₅₀ -	Gold TD ₅₀ 2310	~
Dose (mg/kg/day)	0	40.6								
Incidence	0/50	1/50								
Tumour Site Liver			Tumour Type Tumour- hepatocellular			Probability = 1	NOT SPECIFIED	Lhasa TD ₅₀ -	Gold TD ₅₀ -	>
Tumour Site Lung			Tumour Type Multiple tumour types			Probability <= 0.93	NOT SPECIFIED	Lhasa TD ₅₀ -	Gold TD ₅₀ 1080	>
Tumour Site Lung			Tumour Type Adenoma			Probability <= 0.631	NOT SPECIFIED	Lhasa TD ₅₀ -	Gold TD ₅₀ 225	>
Literature referen	nce(s)									>
Species Mouse		Sex Ma	k Strain Ile Swiss	Route Diet	Exposure time 124 week(s)	Experiment time 124 week(s)				\sim
Tumour Site Caecum			Tumour Type Adenoma- polypoid			Probability = 1	POSITIVE	Lhasa TD ₅₀ -	Gold TD ₅₀	>

What does the future hold for Lhasa CarcDB?

- We want Lhasa CarcDB to be the new Gold Standard in carcinogenicity studies and calculated TD₅₀ values
- Short term goal
 - Increase usage and awareness of CarcDB
 - Create an interface where users can easily calculate their own TD₅₀ values using Lhasa's methodology

What does the future hold for Lhasa CarcDB?

- Adding data beyond the original Gold compounds
 - Additional data from the NTP dataset
 - Additional data from the literature
- Investigating other measures of Carcinogenic potency to calculate and include alongside $\mathrm{TD}_{\mathrm{50}}$
 - Benchmark 10
- Is there any feature you would like to see in CarcDB? We want your feedback.



https://carcdb.lhasalimited.org



shared **knowledge** • shared **progress**

Lhasa Limited Registered Office Granary Wharf House, 2 Canal Wharf, Leeds LS11 5PS Registered Charity (290866) +44 (0)113 394 6020 info@lhasalimited.org www.lhasalimited.org



Company Registration Number 01765239. Registered in England and Wales. VAT Registration Number GB 396 8737 77.

ISO 9001: CERTIFIED